Clinical trials: Mortality
Sepsis, Severe Sepsis
Unsupervised Machine Learning for Clustering of Septic Patients to Determine Optimal Treatment
The focus of this study will be to conduct a prospective, randomized controlled trial (RCT) at Cape Regional Medical Center (CRMC), Oroville Hospital (OH), and UCSF Medical Center (UCSF) in which a fluid treatment-specific…
- Conditions
- Sepsis, Severe Sepsis, Septic Shock
- Trial name
- NCT03752489
- Testing
- Treatment-specific InSight, InSight
- Volunteers
- 51,645 people, healthy volunteers welcome
- Sponsor
- Dascena
Diabetic Nephropathy
To Determine the Effects of Avosentan on Doubling of Serum Creatinine, End Stage Renal Disease and Death in Diabetic Nephropathy
The purpose of this study is to determine whether avosentan (SPP301) is effective in decreasing morbidity and mortality in patients with diabetic nephropathy.
- Trial name
- NCT00120328
- Testing
- SPP301
- Where
- United States
- Volunteers
- 2,364 people
- Sponsor
- Speedel Pharma Ltd.
Pulmonary Arterial Hypertension
Effects of Oral Sildenafil on Mortality in Adults With PAH
This is a blinded study in adult patients with PAH evaluating the relative effects of sildenafil on mortality when administered at the three doses (80 mg, 20 mg or 5 mg, all three times per day [TID]).
- Trial name
- AFFILIATE (NCT02060487)
- Testing
- sildenafil citrate
- Where
- 82 sites in United States, Australia and 21 more
- Volunteers
- 385 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Chronic Kidney Disease (CKD)
Retrospective Analysis Assessing Clinical Risk Factors for Cardiovascular Events and Mortality and Development of a Risk Calculator in Chronic Kidney Disease Stage 5 on Dialysis
The purpose of this study is to evaluate which clinical and laboratory factors are associated with major adverse cardiovascular event (MACE) in chronic kidney disease (CKD) patients on dialysis.
- Trial name
- NCT04042350
- Testing
- Non-interventional
- Where
- Sweden
- Volunteers
- 2,773 people
- Sponsor
- Astellas Pharma Europe Ltd.
Pulmonary Arterial Hypertension
Selexipag (ACT-293987) in Pulmonary Arterial Hypertension
The AC-065A302 (GRIPHON) study is an event-driven Phase 3 study to demonstrate the effect of selexipag on time to first morbidity or mortality event in patients with pulmonary arterial hypertension.
- Trial name
- GRIPHON (NCT01106014)
- Testing
- Selexipag
- Where
- 182 sites in United States, Argentina and 37 more
- Volunteers
- 1,156 people
- Sponsor
- Actelion
Heart Failure With Preserved Ejection Fraction, Heart Failure With Mildly Reduced Ejection Fraction
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
This trial will examine if maridebart cafraglutide as an adjunct to standard of care will lead to a reduction in heart failure (HF) events such as HF hospitalizations and urgent HF visits, cardiovascular (CV) deaths and…
- Conditions
- Heart Failure With Preserved Ejection Fraction, Heart Failure With Mildly Reduced Ejection Fraction, Obesity
- Trial name
- MARITIME-HF (NCT07037459)
- Testing
- Maridebart cafraglutide
- Where
- 657 sites in United States, Argentina and 32 more
- Volunteers
- 5,056 people
- Sponsor
- Amgen
Hematologic Diseases, Hematologic Malignancies
Dose-ranging Study of a Single Administration of T-cell Add-back Depleted of Host Alloreactive Cells in Patients Undergoing a Peripheral Blood Stem Cell Transplant From a Related, Haploidentical Donor
The purpose of this study is to determine the maximum tolerated dose and evaluate the safety of the administration of donor lymphocytes depleted of alloreactive T-cells following a stem cell transplant from a related…
- Trial name
- NCT00993486
- Testing
- Donor lymphocyte preparation depleted of functional host alloreactive T-cells (ATIR)
- Where
- Canada
- Volunteers
- 19 people
- Sponsor
- Kiadis Pharma
COVID-19, Pneumonia
COVID-19 Mortality Prediction Model
The objective of this study is to develop and evaluate an algorithm which accurately predicts mortality in COVID-19, pneumonia and mechanically ventilated ICU patients.
- Conditions
- COVID-19, Pneumonia, Mechanical Ventilation
- Trial name
- NCT04358510
- Testing
- COViage
- Where
- United States
- Volunteers
- 114 people
- Sponsor
- Dascena
Diabetes Type II
A Retrospective Study of Cardiovascular Events Related to the Use of Glucose Lowering Drug Treatment in Primary Care
To describe the type II diabetes population in primary care with special reference to treatment, other diseases and mortality during the last decade.
- Trial name
- ROSE (NCT01121315)
- Where
- Sweden
- Volunteers
- 58,326 people
- Sponsor
- AstraZeneca
Pain
Long-term Opioid Therapy, Misuse and Mortality in Patients With Chronic Non-cancer Pain in Germany
Among patients receiving opioids for noncancer pain, recent research in North America showed a strong association between doses and opioid-related mortality, especially at dosages exceeding thresholds recommended in recent…
- Trial name
- NCT03778450
- Testing
- Analgesics, Opioid, Non-Opioid Analgesic
- Where
- Germany
- Volunteers
- 3,232 people
- Sponsor
- LinkCare GmbH
Chronic Heart Failure
Study of the Survival of Recombinant Human Neuregulin-1β in Chronic Heart Failure (CHF) Patients
The purpose of this study is to evaluate efficacy of rhNRG-1 in reducing the death rate of heart failure.
- Trial name
- NCT01131637
- Testing
- rhNRG-1
- Where
- 43 sites in China
- Volunteers
- 331 people
- Sponsor
- Zensun Sci. & Tech. Co., Ltd.
Aneurysmal Subarachnoid Hemorrhage
Clazosentan in Aneurysmal Subarachnoid Hemorrhage
The aim of this study is to demonstrate that clazosentan, administered as a continuous intravenous infusion at either 5 mg/h or 15 mg/h until Day 14 post aneurysmal subarachnoid hemorrhage (aSAH), reduces the incidence of…
- Trial name
- CONSCIOUS-3 (NCT00940095)
- Testing
- Clazosentan 5 m/h, Clazosentan 15 mg/h
- Where
- 145 sites in United States, Argentina and 26 more
- Volunteers
- 577 people
- Sponsor
- Idorsia Pharmaceuticals Ltd.
Atrial Fibrillation, Atrial Flutter
A Trial With Dronedarone to Prevent Hospitalization or Death in Patients With Atrial Fibrillation
To assess the efficacy of dronedarone in preventing cardiovascular hospitalization or death from any cause in a population of high-risk patients with atrial fibrillation/atrial flutter (AF/AFL).
- Trial name
- ATHENA (NCT00174785)
- Testing
- dronedarone (SR33589)
- Where
- 37 sites in United States, Argentina and 35 more
- Volunteers
- 4,628 people
- Sponsor
- Sanofi
Heart Failure
Registrational Study With Omecamtiv Mecarbil (AMG 423) to Treat Chronic Heart Failure With Reduced Ejection Fraction
The purpose of this study is to determine if treatment with omecamtiv mecarbil when added to standard of care is well tolerated and superior to placebo in reducing the risk of cardiovascular death or heart failure events in…
- Trial name
- GALACTIC-HF (NCT02929329)
- Testing
- Omecamtiv Mecarbil, Standard of Care
- Where
- 1,033 sites in United States, Argentina and 34 more
- Volunteers
- 8,256 people
- Sponsor
- Cytokinetics
Cardiovascular Diseases
A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High-Risk Patients With Hypertriglyceridemia and on Statin
AMR101 (icosapent ethyl [ethyl-EPA]) is a highly purified ethyl ester of eicosapentaenoic acid (EPA) developed by Amarin Pharma Inc.
- Trial name
- REDUCE-IT (NCT01492361)
- Testing
- AMR101, Statin therapy
- Where
- 410 sites in United States, Australia and 9 more
- Volunteers
- 8,179 people
- Sponsor
- Amarin Pharma Inc.
Pulmonary Arterial Hypertension
Study of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension
The AC-055-302/SERAPHIN study will be an event-driven Phase III study, comparing two different doses of macitentan (ACT-064992) (3 and 10 mg) vs placebo in patients with symptomatic PAH.
- Trial name
- SERAPHIN (NCT00660179)
- Testing
- macitentan (ACT-064992)
- Where
- 153 sites in United States, Argentina and 36 more
- Volunteers
- 742 people
- Sponsor
- Actelion
Chronic Heart Failure
Study of the Survival of Recombinant Human Neuregulin-1β in Chronic Heart Failure (CHF) Patients
The purpose of this study is to evaluate efficacy of rhNRG-1 in reducing the death rate of heart failure.
- Trial name
- NCT01541202
- Testing
- rhNRG-1
- Where
- 46 sites in China
- Volunteers
- 679 people
- Sponsor
- Zensun Sci. & Tech. Co., Ltd.
Hyperphosphatemia
Long-term Effect of Lanthanum Carbonate on Bone
Patients enrolled in a previous study (SPD405-309), who were exposed to lanthanum carbonate (Fosrenol), were eligible to continue on any prescribed treatment for hyperphosphatemia, including lanthanum carbonate (Fosrenol), for an…
- Trial name
- NCT00557323
- Testing
- Lanthanum carbonate
- Where
- 19 sites in United States, Germany and 1 more
- Volunteers
- 34 people
- Sponsor
- Shire
Heart Failure, Congestive
ACCLAIM - Advanced Chronic Heart Failure CLinical Assessment of Immune Modulation Therapy
The purpose of this study is to test the safety and efficacy of the Celacade™ system in reducing the risk of mortality and cardiovascular hospitalizations in patients with chronic systolic heart failure.
- Trial name
- NCT00111969
- Testing
- Celacade™ system
- Volunteers
- 2,016 people
- Sponsor
- Vasogen
Congestive Heart Failure
Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM Alternative)
A study to evaluate the effect of Atacand on patients with heart failure with depressed left ventricular function
- Trial name
- NCT00634400
- Testing
- Candesartan
- Volunteers
- 6,268 people
- Sponsor
- AstraZeneca